TBK1: a new target for overcoming cancer immunotherapy resistance

Sci China Life Sci. 2024 Jan;67(1):217-218. doi: 10.1007/s11427-023-2395-y. Epub 2023 Sep 22.

Authors

Jizhong Guan¹, Long Zhang², Fangfang Zhou³

Affiliations

¹ Institutes of Biology and Medical Science, Soochow University, Suzhou, 215123, China.
² MOE Laboratory of Biosystems Homeostasis and Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China. l_zhang@zju.edu.cn.
³ Institutes of Biology and Medical Science, Soochow University, Suzhou, 215123, China. zhoufangfang@suda.edu.cn.

PMID: 37747675
DOI: 10.1007/s11427-023-2395-y

No abstract available

MeSH terms

Humans
Neoplasms* / genetics
Neoplasms* / therapy
Protein Serine-Threonine Kinases* / genetics
Protein Serine-Threonine Kinases* / metabolism
Signal Transduction

Substances

Protein Serine-Threonine Kinases
TBK1 protein, human